Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 12, 2007, Pages 2408-2414

  Hvas, Anne Mette ^a   Sorensen H T ^a   Norengaard, L ^a   Christiansen, K ^a   Ingerslev, J ^a   Sorensen B ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Factor VIII; Hemophilia; Hemostasis; Thrombelastography; Tranexamic acid

Indexed keywords

KOGENATE BAYER; RECOMBINANT BLOOD CLOTTING FACTOR 8; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; FIBRINOLYSIS; HEMOPHILIA A; HUMAN; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOELASTOGRAPHY;

ADULT; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION; DRUG THERAPY, COMBINATION; FACTOR VIII; FIBRINOLYSIS; HEMOPHILIA A; HUMANS; MALE; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; THROMBELASTOGRAPHY; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; TREATMENT OUTCOME; WHOLE BLOOD COAGULATION TIME;

EID: 36348983304     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02755.x     Document Type: Article

References (44)

1. Rizza CR. Haemophilia and related inherited coagulation defects. In: Bloom AL, Thomas DP, eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1987: 819.
2. He S, Blomback M, Ekman GJ, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1:1215-9.
3. Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JC, Nieuwenhuis HK, de Groot PG. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99:175-9.
4. Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86:1035-9.
5. Bouma BN, dem Borne PA, Meijers JC. Factor XI and protection of the fibrin clot against lysis-a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 1998; 80:24-7.
6. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131:645-55.
7. Carr ME Jr, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul Fibrinolysis 1995; 6:567-73.
8. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23:17-25.
9. Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: A randomized, double-blind study in 100 patients. Acta Orthop 2005; 76:314-9.
10. Jansen AJ, Andreica S, Claeys M, D'Haese J, Camu F, Jochmans K. Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. Br J Anaesth 1999; 83:596-601.
11. Hiippala S, Strid L, Wennerstrand M, Arvela V, Mantyla S, Ylinen J, NiemeläH. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. Br J Anaesth 1995; 74:534-7.
12. Veien M, Sorensen JV, Madsen F, Juelsgaard P. Tranexamic acid given intra-operatively reduces blood loss after total knee replacement: A randomized, controlled study. Acta Anaesthesiol Scand 2002; 46:1206-11.
13. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briet E, Büller HR. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints. Lancet 1999; 354:1940-7.
14. Brown RS, Thwaites BK, Mongan PD. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: A double-blind, randomized, placebo-controlled trial. Anesth Analg 1997; 85:963-70.
15. Horrow JC, van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991; 84:2063-70.
16. Wu CC, Ho WM, Cheng SB, Yeh DC, Wen MC, Liu TJ, P'eng FK. Perioperative parenteral tranexamic acid in liver tumor resection: A prospective randomized trial toward a 'blood transfusion'-free hepatectomy. Ann Surg 2006; 243:173-80.
17. Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, Roger SL, Glynn MF. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996; 85:1043-8.
18. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: A prospective randomized study. J Neurosurg 2002; 97:771-8.
19. Dunn CJ, Goa KL. Tranexamic acid: A review of its use in surgery and other indications. Drugs 1999; 57:1005-32.
20. Rizza CR. Inhibitors of fibrinolysis in the treatment of haemophilia. J Clin Pathol Suppl 1980; 14:50-4.
21. Forbes CD, Barr RD, Reid G, Thomson C, Prentice CR, McNicol GP, Douglas AS. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. Br Med J 1972; 2:311-3.
22. Sindet-Pedersen S, Stenbjerg S. Effect of local antifibrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery. J Oral Maxillofac Surg 1986; 44: 703-7.
23. Sindet-Pedersen S, Ramstrom G, Bernvil S, Blomback M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 1989; 320:840-3.
24. Astermark J, Rocino A, von Depka M, van den Berg HM, Gringeri A, Mantovani LG, Morado M, Garrido RP, Schiavoni M, Villar A, Windyga J. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13:38-45.
25. Schulman S, Loogna J, Wallensten R. Minimizing factor requirements for surgery without increased risk. Haemophilia 2004; 10(Suppl. 4):35-40.
26. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1:551-8.
27. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2:102-10.
28. Ingerslev J, Poulsen LH, Sorensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003; 9:348-52.
29. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol 2004; 41:140-4.
30. Fenger-Eriksen C, Anker-Moller E, Heslop J, Ingerslev J, Sorensen B. Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: Improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth 2005; 94:324-9.
31. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: Clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14:469-77.
32. Ingerslev J, Jankowski MA, Weston SB, Charles LA. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004; 2:623-8.
33. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on Good Clinical Practice. (CPMP/ICH/135/95) London: The European Agency for the Evaluation of Medicinal Products, 1997.
34. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006; 26:41-8.
35. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26:2445-53.
36. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96:2534-8.
37. Nesheim M. Fibrinolysis and the plasma carboxypeptidase. Curr Opin Hematol 1998; 5:309-13.
38. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: A possible mechanism of the increased thrombotic risk. Blood 2003; 101:3008-13.
39. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2:402-13.
40. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3:2039-43.
41. Verstraete M. Haemostatic drugs. In: Bloom AL, Thomas DP, eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1987: 607-17.
42. Andersson L, Nilsson IM, Nilehn JE, Hedner U, Grandstrand B, Melander B. Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminoethyl cyclohexane carboxylic acid. Scand J Haematol 1965; 2:230-47.
43. Bennett AE, Ingram GI, Inglish PJ. Antifibrinolytic treatment in haemophilia: A controlled trial of prophylaxis with tranexamic acid. Br J Haematol 1973; 24:83-8.
44. Rainsford SG, Jouhar AJ, Hall A. Tranexamic acid in the control of spontaneous bleeding in severe haemophilia. Thromb Diath Haemorrh 1973; 30:272-9.